Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma

Inclusion Criteria: * Patients must have histologically confirmed esophageal squamous cell carcinoma with relapse disease and the primary tumor have been surgically removed. * With measurable or evaluable disease defined by RECIST 1.1 criteria by multi-slice spiral CT or MRI scan. * \- Failed in or disease progressed after fist-line chemotherapy (If failed in perioperative chemotherapy or disease progressed in 24 weeks after perioperative chemotherapy, the perioperative chemotherapy is regard as first-line chemotherapy ) * \- Patients must have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale * \- Without serious system dysfunction and could tolerate chemotherapy. * \- With normal marrow, liver and renal function: a hemoglobin (HGB) of ≥100g/L (without blood transfusion during 14 days); a neutrophil count of ≥2.0×109/L; a platelet count of ≥100×109/L; a total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL); a creatinine (Cr) of ≤ 1.5 UNL; a creatinine clearance rate ≥ 50ml/min (Cockcroft-Gault); a alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤2.5 UNL or ≤5 UNL in case of liver metastasis. * \- Life expectancy ≥3 months * \- With normal electrocardiogram results and no history of congestive heart failure. * \- Without bleeding and thrombosis disease * \- With normal coagulation function: activated partial thromboplastin time (APTT), prothrombin time (PT) and INR, each ≤ 1.5 x ULN * \- Female subjects of child-bearing potential must agree to use contraceptive measures starting 1 week before the administration of the first dose of apatinib until 8 weeks after discontinuing study drug. Male subjects must agree to use contraceptive measures during the study and 8 weeks after last dose of study drug * \- With written informed consent signed voluntarily by patients themselves or their supervisors witted by doctors. * \- With good compliance and agree to accept follow-up of disease progression and adverse events. Exclusion Criteria: * Patients who have received irinotecan or apatinib in previous treatment. * Primary tumor is not resected. * Uncontrolled hypertension (after treatment with antihypertensive drugs cannot reduced to the normal range: systolic pressure \<140 mmHg and diastolic pressure \<90 mmHg) * With ≥ grade 2 coronary heart disease, arrhythmia (including corrected QT interval prolongation male \>450 ms, women \>470 ms) * Cannot take oral tables including uncontrolled vomiting, chronic diarrhea and intestinal obstruction. * With potential bleeding risk including (1) peptic ulcer and fecal occult blood (++); (2) melena or hematemesis history in last 3 months; (3) fecal occult blood (+) or (+/-) and endoscopy showed ulcer or other diseases with bleeding risk. * With abnormal coagulation function (INR\>1.5 ULN, APTT\>1.5 ULN), * With thrombosis or receiving anticoagulant treatment. * With serious diseases such as congestive heart failure, uncontrolled myocardial infarction and arrhythmia, liver failure and renal failure. * With brain metastasis of tumor * Pregnant or lactated women (premenopausal women must give urine pregnancy test before enrollment).